Interleukin 28B Polymorphisms and Hepatitis C—Translating the Association into Clinical Decision Making

Lavanchy, 2009, The global burden of hepatitis, Liver International, 29, 74, 10.1111/j.1478-3231.2008.01934.x Ghany, 2009, AASLD practice guidelines-diagnosis, management, and treatment of hepatitis C: an update, Hepatology, 49, 1335, 10.1002/hep.22759 Thomas, 2005, Natural history of hepatitis C, Clin Liver Dis, 9, 383, 10.1016/j.cld.2005.05.003 Strader, 1996, The natural history of chronic hepatitis C infection, Eur J Gastroenterol Hepatol, 8, 324, 10.1097/00042737-199604000-00006 Seeff, 2002, National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002, Hepatology, 36, S1, 10.1002/hep.1840360702 Seeff, 2002, Natural history of chronic hepatitis C, Hepatology, 36, S35, 10.1002/hep.1840360706 Liang, 2000, Pathogenesis, natural history, treatment, and prevention of hepatitis C, Ann Intern Med, 132, 296, 10.7326/0003-4819-132-4-200002150-00008 Fattovich, 1997, Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients, Gastroenterology, 112, 463, 10.1053/gast.1997.v112.pm9024300 National Institutes of Health Consensus Development Conference Panel statement, 1997, Management of hepatitis C, Hepatology, 26, 2S, 10.1002/hep.510260701 Manns, 2001, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial, Lancet, 358, 958, 10.1016/S0140-6736(01)06102-5 Fried, 2002, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N Engl J Med, 347, 975, 10.1056/NEJMoa020047 Hadziyannis, 2004, Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose, Ann Intern Med, 140, 346, 10.7326/0003-4819-140-5-200403020-00010 Conjeevaram, 2006, Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1, Gastroenterology, 131, 470, 10.1053/j.gastro.2006.06.008 Muir, 2004, Peginterferon alfa-2b and RBV for the treatment of chronic hepatitis C in blacks and non-Hispanic whites, N Engl J Med, 350, 2265, 10.1056/NEJMoa032502 Attia, 2009, How to use an article about genetic association: a background concepts, JAMA, 301, 74, 10.1001/jama.2008.901 Clark, 2011, IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies, Am J Gastroenterol, 106, 38, 10.1038/ajg.2010.370 Thio, 2008, Host genetic factors and antiviral immune responses to hepatitis C virus, Clin Liver Dis, 12, 713, 10.1016/j.cld.2008.03.002 Rauch, 2009, Host genetic determinants of spontaneous hepatitis C clearance, Pharmacogenomics, 10, 1819, 10.2217/pgs.09.121 Little, 2009, STrengthening the REporting of Genetic Association studies (STREGA)-an extension of the STROBE statement, Eur J Clin Invest, 39, 247, 10.1111/j.1365-2362.2009.02125.x Asselah, 2007, Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C, Semin Liver Dis, 27, 13, 10.1055/s-2006-960168 Rauch, 2010, The recent breakthroughs in the understanding of host genomics in hepatitis C, Eur J Clin Invest, 40, 950, 10.1111/j.1365-2362.2010.02337.x Ahlenstiel, 2010, IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice, J Gastroenterology, 45, 903, 10.1007/s00535-010-0287-4 Ge, 2009, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance, Nature, 461, 399, 10.1038/nature08309 Tanaka, 2009, Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C, Nat Genet, 41, 1105, 10.1038/ng.449 Suppiah, 2009, IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy, Nat Genet, 41, 1100, 10.1038/ng.447 Rauch, 2010, Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study, Gastroenterology, 138, 1338, 10.1053/j.gastro.2009.12.056 Romero-Gomez, 2011, Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment, Liver International, 31, 443, 10.1111/j.1478-3231.2011.02449.x Aghemo, 2010, Genetic variation in interleukin-28B predicts hepatitis C treatment-induced viral clearance in genotype 1 patients: the dawn of a new era, Gastroenterology, 138, 2546, 10.1053/j.gastro.2010.04.037 Asrani, 2010, Predicting response to pegylated interferon/ribavirin-based therapy in genotype 1 chronic hepatitis C patients: results of 3 independent genome-wide association studies, Gastroenterology, 138, 1622, 10.1053/j.gastro.2010.02.023 Shackel, 2010, Snipping away at hepatitis C, Hepatology, 51, 703, 10.1002/hep.23490 Iadonato, 2009, Genomics: hepatitis C virus gets personal, Nature, 461, 357, 10.1038/461357a Li, 2011, Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: a meta-analysis, Hepatol Mon, 11, 163 Stattermayer, 2011, Impact of IL28B genotype on the early and sustained virological response in treatment-naïve patients with chronic hepatitis C, Clin Gastroenterol Hepatol, 9, 344, 10.1016/j.cgh.2010.07.019 Mangia, 2010, IL28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 or 3 who do not achieve a rapid virologic response, Gastroenterology, 139, 821, 10.1053/j.gastro.2010.05.079 Rallón, 2010, Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients, AIDS, 24, F23, 10.1097/QAD.0b013e3283391d6d Moghaddam, 2011, IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection, Hepatology, 53, 746, 10.1002/hep.24154 Sazzarin, 2011, Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients, J Hepatol, 54, 415, 10.1016/j.jhep.2010.07.041 Yu, 2011, Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients, Hepatology, 53, 7, 10.1002/hep.23976 Kawaoka, 2011, Predictive value of the IL28B polymorphisms on the effect of interferon therapy in chronic hepatitis C patients with genotype 2a and 2b, J Hepatol, 54, 408, 10.1016/j.jhep.2010.07.032 Sakamoto, 2011, Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b, J Med Virol, 83, 871, 10.1002/jmv.22038 Montes-Cano, 2010, Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes, Hepatology, 52, 33, 10.1002/hep.23624 Thomas, 2009, Genetic variation in IL28B and spontaneous clearance of hepatitis C virus, Nature, 461, 798, 10.1038/nature08463 Tillman, 2010, A polymorphism near IL28B is associated with spontaneous clearance, of acute hepatitis C virus and jaundice, Gastroenterology, 139, 1586, 10.1053/j.gastro.2010.07.005 Grebely, 2010, Potential role for IL28B genotype in treatment decision-making in recent hepatitis C virus infection, Hepatology, 52, 1216, 10.1002/hep.23850 Wiegand, 2006, Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study, Hepatology, 43, 250, 10.1002/hep.21043 Kamal, 2004, Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics, Hepatology, 39, 1721, 10.1002/hep.20266 Jaeckel, 2001, Treatment of acute hepatitis C with interferon alfa-2b, N Engl J Med, 345, 1452, 10.1056/NEJMoa011232 Marcello, 2006, Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics, Gastroenterology, 131, 1887, 10.1053/j.gastro.2006.09.052 Pineda, 2010, Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus, Clin Infect Dis, 51, 788, 10.1086/656235 Fukhara, 2010, Variants in IL28B in liver recepients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C, Gastroenterology, 139, 1577, 10.1053/j.gastro.2010.07.058 Guillouche, 2011, Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation, Aliment Pharmacol Ther, 33, 163, 10.1111/j.1365-2036.2010.04505.x Akuta, 2010, Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin, Hepatology, 52, 421, 10.1002/hep.23690 Craxì, 2011, EASL Clinical Practice Guidelines: management of hepatitis C virus infection, J Hepatol Hofer, 2002, Spontaneous viral clearance in patients with acute hepatitis C: predictability by repeated measurements of serum HCV concentration, Hepatology, 36, 286A Perlman, 2011, The Il28B genotype: how will it affect the care of patients with hepatitis C virus infection?, Curr Gastroenterol Rep, 13, 78, 10.1007/s11894-010-0161-9